SKU: F041

Size  
Quantity:
 
Price: make selection(s)
Description

Flomoxef Sodium is a β -lactam inhibitor and member of the oxacephem family and exhibits antibiotic properties.  It has been used for respiratory infections and bone diseases (ie osteoporosis).  It was synthesized in 1982 by Shionogi & Co, Osaka, Japan in order to overcome disulfiram actions. 

    CAS Number

    92823-03-5

    Molecular Formula

    C15H18F2N6NaO7S2

    Molecular Weight

    519.451

    Mechanism of Action

    Flomoxef Sodium is a ╬▓-lactam inhibitor that acts by inhibiting cell-wall synthesis. This is performed by binding to penicillin-binding proteins which prevents the transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to the inhibition of cell-wall biosynthesis.

    Spectrum

    Flomoxef Sodium is effective for Gram-negative and Gram-positive bacteria including MRSA. It is also effective for Nocardia.

Applications

    Microbiology Applications

    Flomoxef is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.  Representative MIC values include:

      • B. fragilis  0.5 µg/mL – ≥ 128 µg/mL
      • MRSA  4 µg/mL - ≥ 16 µg/mL

    For a representative list of Flomoxef MIC values, click here.

Specifications

    Form

    powder

    Appearance

    white or off-white powder

    Source

    synthetic

References

    References

    Gilman AG, Rall TW, and Nies AS (eds) (1990)  Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Macmillan Publishing Co, New York, NY

    Ito M and Ishigami T (1991)  The meaning of the development of flomoxef and clinical experience in Japan.  Infection 19 (suppl 5):S253-S257  PMID 1783441

    Kitahara T et al (2004)  Antimicrobial activity of saturated fatty acids and fatty amines against Methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 27(9):1321-1326  PMID 15340213

    Ruckdeschel G and Eder W (1988)  Comparative in vitro activity of the new oxacephem antibiotic, flomoxef. Eur. J. Clin. Microbiol. Infect. Dis. 7:687-691  PMID 3143586

    Tsuji T, Satoh H, Narisada M, Hamashima Y and Yoshida T (1985)  Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic. J. Antibiotics 38 (4):466-476 PMID 4008339

    Yazawa K, Mikami Y, Uno J, Otozai K, Arai T (1989)  In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins. J. Antimicrob. Chemother. 24(6):921-925  PMID 2621177

Other Items In This Category